CUMYL-PEGACLONE
Overview[edit]
CUMYL-PEGACLONE is a synthetic cannabinoid that has been used in recreational drugs. It is a potent agonist of the cannabinoid receptors, primarily the CB1 receptor. CUMYL-PEGACLONE is part of a class of compounds known as indazole-based synthetic cannabinoids, which have been developed for research purposes but have also been found in designer drugs.
Chemical Structure[edit]
CUMYL-PEGACLONE is chemically classified as an indazole-3-carboxamide. Its structure includes a cumyl group attached to the nitrogen of the indazole ring, and a pentyl chain linked to the carbonyl group. The presence of these groups contributes to its high affinity for cannabinoid receptors.
Pharmacology[edit]
CUMYL-PEGACLONE acts as a full agonist at the CB1 receptor, which is primarily responsible for the psychoactive effects of cannabinoids. The activation of CB1 receptors by CUMYL-PEGACLONE can lead to effects similar to those of tetrahydrocannabinol (THC), the active component of cannabis. These effects may include euphoria, altered perception, and cognitive impairment.
Legal Status[edit]
Due to its potential for abuse and lack of medical use, CUMYL-PEGACLONE is controlled in many jurisdictions. It is often included in legislation targeting new psychoactive substances (NPS) and synthetic cannabinoids. The legal status can vary significantly between countries and regions.
Health Risks[edit]
The use of CUMYL-PEGACLONE, like other synthetic cannabinoids, can pose significant health risks. Adverse effects may include tachycardia, hypertension, anxiety, paranoia, and in severe cases, psychosis. The variability in potency and purity of synthetic cannabinoid products increases the risk of overdose and toxic reactions.
